Lab
S&G Labs Hawaii LLC
S&G Labs Hawaii LLC was paid $15.13M by Medicaid between Jan 2018 and Dec 2024, across 45 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 26% of everything it billed.
33Billing provider infoS&G LABS HAWAII LLC
KAILUA KONA, HI 96740
KAILUA KONA, HI 96740
33aNPI1477925188assigned 10/21/2015
33bProvider typeClinical Medical Laboratory
28Total paid$15.13M
24GClaims409,562
24DCodes billed45
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Hawaii
Rank by total paid#3 of 18
Median peer was paid$163K
This provider vs. median93×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 94,128 | $1.68M | |
| 2019 | 88,297 | $2.13M | |
| 2020 | 46,613 | $2.62M | |
| 2021 | 61,632 | $3.10M | |
| 2022 | 44,820 | $2.10M | |
| 2023 | 42,418 | $1.83M | |
| 2024incomplete | 31,654 | $1.66M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 26% | 103,220 | 56,764 | $3.95M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 25% | 54,327 | 34,016 | $3.79M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 16% | 24,594 | 13,844 | $2.35M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 14% | 41,271 | 22,671 | $2.15M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 6.3% | 16,792 | 11,079 | $960K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 3.4% | 5,480 | 2,787 | $508K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.5% | 12,347 | 9,111 | $222K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.0% | 9,027 | 5,380 | $155K |
| 80346 | <1% | 5,386 | 3,167 | $85K | |
| 80365 | <1% | 5,243 | 3,118 | $84K | |
| 80324 | <1% | 5,567 | 3,296 | $83K | |
| 80361 | <1% | 4,386 | 2,654 | $76K |
33 more codes
| 80356 | <1% | 3,887 | $68K | |
| 80353 | <1% | 4,641 | $68K | |
| 80358 | <1% | 3,447 | $56K | |
| 80349 | <1% | 3,356 | $50K | |
| 80321 | <1% | 3,453 | $49K | |
| 80354 | <1% | 2,666 | $44K | |
| 83992 | <1% | 12,252 | $38K | |
| 80348 | <1% | 2,524 | $35K | |
| 80360 | <1% | 2,893 | $34K | |
| 80375 | <1% | 2,674 | $31K | |
| 80323 | <1% | 2,339 | $29K | |
| 80359 | <1% | 1,786 | $23K | |
| 80362 | <1% | 2,107 | $23K | |
| 80369 | <1% | 1,614 | $21K | |
| 80373 | <1% | 1,284 | $17K | |
| 82570 | <1% | 20,391 | $17K | |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | <1% | 2,935 | $14K |
| 83986 | <1% | 20,413 | $14K | |
| 80355 | <1% | 1,053 | $13K | |
| 81003 | <1% | 20,380 | $10K | |
| 80366 | <1% | 789 | $10K | |
| 80370 | <1% | 795 | $10K | |
| 80372 | <1% | 755 | $9K | |
| 80371 | <1% | 1,150 | $7K | |
| 80368 | <1% | 699 | $6K | |
| 80357 | <1% | 597 | $4K | |
| 84560 | <1% | 589 | $3K | |
| 80342 | <1% | 119 | $2K | |
| 80332 | <1% | 35 | $273.27 | |
| 82977 | <1% | 21 | $107.96 | |
| 80338 | <1% | 20 | $91.40 | |
| 86328 | <1% | 40 | $90.46 | |
| S9999 | Sales tax | 0% | 218 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPUANA, LYNN (CEO)
| Provider | Location | Paid |
|---|---|---|
| Big Island Pain Center INC. | Hilo, HI | $2.70M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.